Biomedicine · global
Identifying Liver Signals in Blood: Extracellular Vesicle Research Finds Molecular Clues to Liver Cancer
Isolating vesicles released by liver cells before reading their proteins and RNA may help clarify disease signals mixed together in blood. A new Mursla study supports this approach to biomarker development but has not yet demonstrated accurate liver cancer screening.
Blood carries molecular messages released by tissues throughout the body. One challenge in identifying liver cancer from these messages is determining where the signals originate. A study announced by Mursla Bio sought to first enrich extracellular vesicles derived from hepatocytes and then analyze their contents, revealing clues to liver disease otherwise obscured in mixed samples.
Published in the Journal of Extracellular Vesicles, the study compared plasma from patients with hepatocellular carcinoma, patients with cirrhosis, and healthy donors. The researchers used the NEXPLOR platform to obtain hepatocyte-derived vesicles and conducted a paired analysis against conventional vesicle isolation from the same plasma samples. Each clinical sample required less than 2 milliliters. The company announced the research on October 13, and Clinical Lab Products also reported on the comparison.
Extracellular vesicles are tiny membrane-bound particles released by cells that carry substances including proteins and RNA. NEXPLOR uses antibodies that recognize four markers to enrich hepatocyte-derived vesicles, reducing background interference from vesicles originating from platelets and white blood cells. This allows researchers to link molecular changes to a more clearly defined cellular source.
Protein analysis showed that the hepatocyte vesicle enrichment method identified 57% more proteins than conventional vesicle isolation, with better reproducibility. The two methods revealed different contents: conventional preparations were dominated by proteins secreted into plasma, such as albumin, while enriched samples contained more proteins associated with mitochondria, the cytoplasm, and cell membranes, providing another window into the internal state of hepatocytes.
When the researchers directly compared hepatocellular carcinoma with cirrhosis, the enriched samples revealed cancer-associated proteins and interconnected protein networks. The paired conventional vesicle preparations did not resolve the same findings. This comparison is particularly important: for future use in liver disease surveillance, a test must be able to distinguish cancer from existing liver disease, rather than simply distinguish people with disease from healthy people.
Small RNA sequencing showed a similar pattern. In hepatocyte vesicles, 5 microRNAs were elevated in liver cancer compared with cirrhosis, versus 21 in conventional vesicles. Although fewer in number, the former corresponded to pathways more closely related to hepatocellular carcinoma signaling, while the latter mainly involved broader inflammatory responses. This suggests that the value of biomarkers depends not only on their number but also on whether they retain the context of their tissue of origin.
However, molecular differences do not yet establish diagnostic performance. This study supports vesicle enrichment and biomarker discovery but has not yet established prospective accuracy for liver cancer detection. The 57% figure refers to an increase in the number of proteins identified and cannot be interpreted as an improvement in the cancer detection rate. Further work in independent study populations is still needed to confirm the sensitivity and specificity of the candidate signals and whether they can help in actual surveillance.